Innate Pharma revenue was €93.95 m in FY, 2018 which is a 113.4% year over year increase from the previous period.
Innate Pharma revenue breakdown by business segment: 85.0% from Revenue from collaboration and licensing agreements and 15.0% from Government financing for research expenditures
|FY, 2017||FY, 2018|
|Revenue from collaboration and licensing agreements||32.63 m||79.89 m|
|Government financing for research expenditures||11.40 m||14.06 m|